Literature DB >> 26317465

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.

David Roulois1, Helen Loo Yau2, Rajat Singhania1, Yadong Wang1, Arnavaz Danesh1, Shu Yi Shen1, Han Han3, Gangning Liang3, Peter A Jones3, Trevor J Pugh2, Catherine O'Brien4, Daniel D De Carvalho5.   

Abstract

DNA-demethylating agents have shown clinical anti-tumor efficacy via an unknown mechanism of action. Using a combination of experimental and bioinformatics analyses in colorectal cancer cells, we demonstrate that low-dose 5-AZA-CdR targets colorectal cancer-initiating cells (CICs) by inducing viral mimicry. This is associated with induction of dsRNAs derived at least in part from endogenous retroviral elements, activation of the MDA5/MAVS RNA recognition pathway, and downstream activation of IRF7. Indeed, disruption of virus recognition pathways, by individually knocking down MDA5, MAVS, or IRF7, inhibits the ability of 5-AZA-CdR to target colorectal CICs and significantly decreases 5-AZA-CdR long-term growth effects. Moreover, transfection of dsRNA into CICs can mimic the effects of 5-AZA-CdR. Together, our results represent a major shift in understanding the anti-tumor mechanisms of DNA-demethylating agents and highlight the MDA5/MAVS/IRF7 pathway as a potentially druggable target against CICs.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26317465      PMCID: PMC4843502          DOI: 10.1016/j.cell.2015.07.056

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  37 in total

1.  Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine.

Authors:  Adam R Karpf; Amy W Lasek; Ted O Ririe; Adrianne N Hanks; Douglas Grossman; David A Jones
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

2.  Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses.

Authors:  Friedemann Weber; Valentina Wagner; Simon B Rasmussen; Rune Hartmann; Søren R Paludan
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Gene body methylation can alter gene expression and is a therapeutic target in cancer.

Authors:  Xiaojing Yang; Han Han; Daniel D De Carvalho; Fides D Lay; Peter A Jones; Gangning Liang
Journal:  Cancer Cell       Date:  2014-09-25       Impact factor: 31.743

4.  Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells.

Authors:  A R Karpf; P W Peterson; J T Rawlins; B K Dalley; Q Yang; H Albertsen; D A Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

5.  MAVS, cGAS, and endogenous retroviruses in T-independent B cell responses.

Authors:  Ming Zeng; Zeping Hu; Xiaolei Shi; Xiaohong Li; Xiaoming Zhan; Xiao-Dong Li; Jianhui Wang; Jin Huk Choi; Kuan-wen Wang; Tiana Purrington; Miao Tang; Maggy Fina; Ralph J DeBerardinis; Eva Marie Y Moresco; Gabriel Pedersen; Gerald M McInerney; Gunilla B Karlsson Hedestam; Zhijian J Chen; Bruce Beutler
Journal:  Science       Date:  2014-12-19       Impact factor: 47.728

6.  Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3.

Authors:  Rashu B Seth; Lijun Sun; Chee-Kwee Ea; Zhijian J Chen
Journal:  Cell       Date:  2005-09-09       Impact factor: 41.582

7.  Identification and expansion of human colon-cancer-initiating cells.

Authors:  Lucia Ricci-Vitiani; Dario G Lombardi; Emanuela Pilozzi; Mauro Biffoni; Matilde Todaro; Cesare Peschle; Ruggero De Maria
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

8.  RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.

Authors:  P Duewell; A Steger; H Lohr; H Bourhis; H Hoelz; S V Kirchleitner; M R Stieg; S Grassmann; S Kobold; J T Siveke; S Endres; M Schnurr
Journal:  Cell Death Differ       Date:  2014-07-11       Impact factor: 15.828

9.  Diverse intracellular pathogens activate type III interferon expression from peroxisomes.

Authors:  Charlotte Odendall; Evelyn Dixit; Fabrizia Stavru; Helene Bierne; Kate M Franz; Ann Fiegen Durbin; Steeve Boulant; Lee Gehrke; Pascale Cossart; Jonathan C Kagan
Journal:  Nat Immunol       Date:  2014-06-22       Impact factor: 25.606

10.  Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.

Authors:  Huili Li; Katherine B Chiappinelli; Angela A Guzzetta; Hariharan Easwaran; Ray-Whay Chiu Yen; Rajita Vatapalli; Michael J Topper; Jianjun Luo; Roisin M Connolly; Nilofer S Azad; Vered Stearns; Drew M Pardoll; Nancy Davidson; Peter A Jones; Dennis J Slamon; Stephen B Baylin; Cynthia A Zahnow; Nita Ahuja
Journal:  Oncotarget       Date:  2014-02-15
View more
  475 in total

1.  Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.

Authors:  Catharina Wenk; Anne-Kathrin Garz; Sonja Grath; Christina Huberle; Denis Witham; Marie Weickert; Roberto Malinverni; Julia Niggemeyer; Michèle Kyncl; Judith Hecker; Charlotta Pagel; Christopher B Mulholland; Catharina Müller-Thomas; Heinrich Leonhardt; Florian Bassermann; Robert A J Oostendorp; Klaus H Metzeler; Marcus Buschbeck; Katharina S Götze
Journal:  Blood Adv       Date:  2018-12-11

2.  Take two: Combining immunotherapy with epigenetic drugs to tackle cancer.

Authors:  Karen Weintraub
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

3.  Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.

Authors:  Bin Du; David J Waxman
Journal:  Cancer Lett       Date:  2019-11-22       Impact factor: 8.679

4.  5-Aza-2'-deoxycytidine induces a greater inflammatory change, at the molecular levels, in normoxic than hypoxic tumor microenvironment.

Authors:  Ísis Salviano Soares de Amorim; Juliana Alves Rodrigues; Pedro Nicolau; Sandra König; Carolina Panis; Adenilson de Souza da Fonseca; Andre Luiz Mencalha
Journal:  Mol Biol Rep       Date:  2021-02-05       Impact factor: 2.316

5.  Epigenetic Compensation Promotes Liver Regeneration.

Authors:  Shuang Wang; Chi Zhang; Dan Hasson; Anal Desai; Sucharita SenBanerjee; Elena Magnani; Chinweike Ukomadu; Amaia Lujambio; Emily Bernstein; Kirsten C Sadler
Journal:  Dev Cell       Date:  2019-06-20       Impact factor: 12.270

6.  TET family dioxygenases and the TET activator vitamin C in immune responses and cancer.

Authors:  Xiaojing Yue; Anjana Rao
Journal:  Blood       Date:  2020-09-17       Impact factor: 22.113

7.  Breaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation.

Authors:  Sadeem Ahmad; Xin Mu; Fei Yang; Emily Greenwald; Ji Woo Park; Etai Jacob; Cheng-Zhong Zhang; Sun Hur
Journal:  Cell       Date:  2018-01-25       Impact factor: 41.582

8.  Depletion of H3K36me2 recapitulates epigenomic and phenotypic changes induced by the H3.3K36M oncohistone mutation.

Authors:  Kartik N Rajagopalan; Xiao Chen; Daniel N Weinberg; Haifen Chen; Jacek Majewski; C David Allis; Chao Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

9.  Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine.

Authors:  Minmin Liu; Hitoshi Ohtani; Wanding Zhou; Andreas Due Ørskov; Jessica Charlet; Yang W Zhang; Hui Shen; Stephen B Baylin; Gangning Liang; Kirsten Grønbæk; Peter A Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

10.  Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine.

Authors:  Hitoshi Ohtani; Andreas D Ørskov; Alexandra S Helbo; Linn Gillberg; Minmin Liu; Wanding Zhou; Johanna Ungerstedt; Eva Hellström-Lindberg; Weili Sun; Gangning Liang; Peter A Jones; Kirsten Grønbæk
Journal:  Cancer Res       Date:  2020-04-03       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.